Krystal Biotech, Inc. 4

President and CEO Krish S. Krishnan sold 24,696 shares of Krystal Biotech, Inc. common stock on 2026-09-04 for about $8.9 million under a Rule 10b5-1 plan.

On September 4, 2026, Krish S. Krishnan, President and CEO of Krystal Biotech, Inc., executed a series of open-market sales of the company’s common stock under a previously adopted Rule 10b5-1 trading plan, disposing of an aggregate 24,696 shares at weighted-average prices ranging from approximately $354.54 to $366.56 per share, for total proceeds of roughly $8.9 million. These sales, all reported as direct holdings (code “D”), reduced his directly held stake from 1,372,023 shares to 1,347,543 shares, while he continues to have additional indirect beneficial interests through various family trusts, and his spouse’s holdings are reported separately and disclaimed except for his pecuniary interest.

Filing Facts

CIK

1711279

Ticker

KRYS

Form

4

Source Type

fda

Accession

0001298709-26-000011

Alert Tier

7